Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.

Autor: Zaaijer LH; Department of Obstetrics and Gynaecology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van Doorn HC; Department of Obstetrics and Gynaecology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Mourits MJ; Department of Obstetrics and Gynaecology, Medical Centre Groningen, University of Groningen, Groningen, The Netherlands., van Beurden M; Department of Obstetrics and Gynaecology, Netherlands Cancer Institute NKI-AVL, Amsterdam, The Netherlands., de Hullu JA; Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The Netherlands., Adank MA; Department of Clinical Genetics, VU Medical Centre, Amsterdam, The Netherlands., van Lonkhuijzen LR; Center for Gynecologic Oncology, Academic Medical Centre, Amsterdam, The Netherlands., Vasen HF; Foundation for the Detection of Hereditary Tumours (STOET), Leiden, The Netherlands., Slangen BF; Department of Obstetrics and Gynaecology, Maastricht University Medical Centre, Maastricht, The Netherlands., Gaarenstroom KN; Department of Obstetrics and Gynaecology, Leiden University Medical Centre, Leiden, The Netherlands., Zweemer RP; Department Gynaecological Oncology, UMC Utrecht Cancer Centre, Utrecht, The Netherlands., Vencken PM; Department of Obstetrics and Gynaecology, Bravis Hospital, Bergen op Zoom, The Netherlands., Seynaeve C; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Kriege M; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Publikováno v: British journal of cancer [Br J Cancer] 2016 Nov 08; Vol. 115 (10), pp. 1174-1178. Date of Electronic Publication: 2016 Oct 18.